← All trials
NCT04820751
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2021
- Primary completion
- Nov 1, 2021
- Completion date
- Jan 1, 2022
- First posted
- Mar 29, 2021
- Last posted
- Apr 2, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ciusss de L'Est de l'Île de MontréalLead sponsor
- Covid-19 Early Treatment FundCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.